NRXP vs. THTX, ENLV, ACXP, DARE, APRE, ACST, UBX, VIRX, LPCN, and BIOR
Should you be buying NRx Pharmaceuticals stock or one of its competitors? The main competitors of NRx Pharmaceuticals include Theratechnologies (THTX), Enlivex Therapeutics (ENLV), Acurx Pharmaceuticals (ACXP), Daré Bioscience (DARE), Aprea Therapeutics (APRE), Acasti Pharma (ACST), Unity Biotechnology (UBX), Viracta Therapeutics (VIRX), Lipocine (LPCN), and Biora Therapeutics (BIOR). These companies are all part of the "pharmaceutical preparations" industry.
NRx Pharmaceuticals (NASDAQ:NRXP) and Theratechnologies (NASDAQ:THTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership, community ranking and media sentiment.
NRx Pharmaceuticals has a net margin of 0.00% compared to Theratechnologies' net margin of -23.04%.
Theratechnologies received 22 more outperform votes than NRx Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave NRx Pharmaceuticals an outperform vote while only 52.73% of users gave Theratechnologies an outperform vote.
Theratechnologies has higher revenue and earnings than NRx Pharmaceuticals. Theratechnologies is trading at a lower price-to-earnings ratio than NRx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, NRx Pharmaceuticals had 9 more articles in the media than Theratechnologies. MarketBeat recorded 9 mentions for NRx Pharmaceuticals and 0 mentions for Theratechnologies. NRx Pharmaceuticals' average media sentiment score of 0.37 beat Theratechnologies' score of 0.00 indicating that NRx Pharmaceuticals is being referred to more favorably in the media.
NRx Pharmaceuticals has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500. Comparatively, Theratechnologies has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500.
4.3% of NRx Pharmaceuticals shares are held by institutional investors. 21.1% of NRx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
NRx Pharmaceuticals and Theratechnologies tied by winning 7 of the 14 factors compared between the two stocks.
Get NRx Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for NRXP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NRXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NRx Pharmaceuticals Competitors List
Related Companies and Tools
